表紙
市場調査レポート

CRISPRの世界市場の考察・機会分析・市場シェア・将来予測

Global CRISPR Market Insights, Opportunity Analysis, Market Shares and Forecast 2016 - 2022

発行 Occams Business Research & Consulting Pvt. Ltd. 商品コード 348577
出版日 ページ情報 英文 140 Pages
納期: お問合せ
価格
本日の銀行送金レート: 1USD=102.06円で換算しております。
Back to Top
CRISPRの世界市場の考察・機会分析・市場シェア・将来予測 Global CRISPR Market Insights, Opportunity Analysis, Market Shares and Forecast 2016 - 2022
出版日: 2016年04月29日 ページ情報: 英文 140 Pages
概要

世界のCRISPR市場は2015〜2021年にかけ、CAGR43%で拡大すると予測されています。CRISPRはシンプルかつ効率的で費用対効果の高い新技術で、高度な研究を行なうバイオテクノロジー企業や製薬業界による導入が広がっていることが市場の拡大を促進しています。

レポートでは、世界のCRISPR市場について調査し、市場の動向と2021年までの収益予測と成長率、業界動向、競合、国別動向のほか、参入する主要企業のプロファイルなどをまとめています。

第1章 イントロダクション

第2章 市場概要

  • CRISPR:イントロダクション
  • バリューチェーン分析
  • 主な購買基準
  • 研究開発
  • CRISPR対従来の遺伝子編集ツール
  • CRISPR:新たな取り組み
  • 戦略的提言と結論

第3章 セクター分析

第4章 市場決定因子

  • 促進因子
    • 創薬市場の増加
    • 合成遺伝子の需要
    • 出生時の遺伝病の罹患率上昇
    • 年齢に関係する遺伝疾患
    • 医療用研究開発予算の増加
    • ベンチャーキャピタル
  • 阻害因子
    • CRISPR遺伝子編集ツールの誤用に関する倫理的問題
    • 限定された認識
    • 新興市場における制限
  • 課題
    • CRISPR遺伝子編集が遺伝子外科市場を開放する
    • アジアにおける新興の研究開発受託市場
  • 機会
    • 特許侵害
    • 代替的遺伝子編集ツールの登場

第5章 市場セグメンテーション

  • 用途別
  • エンドユーザー別
  • 競合インテリジェンス

第6章 地域別分析

  • 北米
  • 欧州
  • アジア太平洋地域
  • その他

第7章 企業プロファイル

  • Thermo Fisher Scientific
  • Editas Medicine
  • Caribou Biosciences
  • CRISPR therapeutics
  • Intellia
  • Cellectis
  • Horizon discovery PLC
  • Sigma Aldrich
  • Precision biosciences
  • GenScript
  • Sangamo Biosciences Inc.
  • Lonza group limited
  • Integrated DNA technologies
  • New England Biolabs
  • Oregene Technologies
  • Transposgen Biopharmaceuticals

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: HBI-2021015

Clustered regularly-interspaced short palindromic repeats also known as CRISPR is a gene editing tool. CRIPSR commercialization began in 2012 with emergence of number of startups and venture capitalists and showing their interest in infusing money into this technology. Academic and research firms are the main consumers of CRISPR gene editing tool followed by biotechnology companies. The number of patents for CRISPR is outclassing the patents of other gene editing tools such as ZFN and TALEN. The market is driven by high demand for plasmids, synthetic genes and high quality gene slicing techniques. Growing drug discovery, biotechnology and proteomics markets are also driving the market growth.

The market is This is driven by the fact that CRISPR is a new technology which is simple, more efficient and cost effective as compared to its peers. High adoption both in biotech and pharma industry along with high level of research is also responsible for high growth rate.

The market for CRISPR technology is niche. The number of companies are still very less and most of the companies are start-ups which are going through rounds of funding. Some of the major companies include Editas, Intellia, Sigma Eldrich, Oregene, Gene Script, Thermo Fisher Scientific and others. Most of the companies are working on developing CRISPR products along with the approval and commercialization of such products. These companies have successfully attracted major investments from big VC firms and companies such as Google and DuPont. These companies are relying on the disruptive nature of the technology. CRISPR has the capability to open new markets for gene surgery and genetically modified organisms. However, there are major concerns from the scientific community regarding the misuse of such technology in human cloning. Geographically North America leads the market race followed by Europe and Asia Pacific.

Companies profiled include

  • 1. Thermo Fisher Scientific
  • 2. Editas Medicine
  • 3. Caribou Biosciences
  • 4. CRISPR therapeutics
  • 5. Intellia
  • 6. Cellectis
  • 7. Horizon discovery PLC
  • 8. Sigma Aldrich
  • 9. Precision biosciences
  • 10. GenScript
  • 11. Sangamo Biosciences Inc.
  • 12. Lonza group limited
  • 13. Integrated DNA technologies
  • 14. New England Biolabs
  • 15. Oregene Technologies
  • 16. Transposgen Biopharmaceuticals

This Occams Research report covers

  • 1. Historical data
  • 2. Revenue forecasts, growth rates and CAGR up to 2021
  • 3. Industry Analysis
  • 4. Competitive Analysis
  • 5. Key geographic growth data

Table of Contents

1. Executive Summary

  • 1.1. Estimation Methodology

2. Market Overview

  • 2.1. CRISPR- Introduction
  • 2.2. Value chain analysis
  • 2.3. Key buying criteria
  • 2.4. Research and development
    • 2.4.1. Patent analysis
  • 2.5. CRISPR vs. Conventional gene editing tools
    • 2.5.1. TALEN
    • 2.5.2. ZFN
  • 2.6. CRISPR: Novel initiatives
    • 2.6.1. CRISPR/Cas9 technology
    • 2.6.2. CRISPR as a gene editing tool to treat genetic disorders.
    • 2.6.3. CRISP as a gene editing tool in drug development.
  • 2.7. Strategic Recommendation and conclusion

3. Sector Analysis

  • 3.1. Gene Editing Market

4. Market Determinants

  • 4.1. Drivers
    • 4.1.1. Rise in drug discovery market
    • 4.1.2. Demand for synthetic genes
    • 4.1.3. High prevalence of genetic birth disorders
    • 4.1.4. Age related genetic disorders
    • 4.1.5. Rise in the healthcare research and development budgets
    • 4.1.6. Venture capital
  • 4.2. Restraints
    • 4.2.1. Ethical issues related to misuse of CRISPR gene editing tool
    • 4.2.2 Limited awareness
    • 4.2.3. Limited presence in Emerging markets
  • 4.3. Opportunities
    • 4.3.1 CRISPR gene editing can open the market for gene surgery.
    • 4.3.2. Emerging contract research market in Asia
  • 4.4. Challenges
    • 4.4.1. Patent infringement
    • 4.4.2. Presence of alternative gene editing tools

5. Market Segmentation

  • 5.1. By Application
    • 5.1.1. Genome Editing
    • 5.1.2. Genetic engineering
    • 5.1.3. gRNA Database/Gene Library
    • 5.1.4. CRISPR Plasmid
    • 5.1.5. Human Stem Cells
    • 5.1.6. Genetically modified organisms/crops
    • 5.1.7. Cell line engineering
  • 5.2. By End user
    • 5.2.1. Biotechnology companies
    • 5.2.2. Pharmaceutical companies
    • 5.2.3. Academic Institutes
    • 5.2.4. Research and development institutes
  • 5.3. Competitive Intelligence
    • 5.3.1. Merger and Acquisitions
    • 5.3.2. Innovation
    • 5.3.3. Venture capital funding

6. Geographical Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. United Kingdom
    • 6.2.2. France
    • 6.2.3. Germany
    • 6.2.4. Spain
    • 6.2.5. Italy
  • 6.3. Asia Pacific
    • 6.3.1. China
    • 6.3.2. Japan
    • 6.3.3. India
  • 6.4. Rest of the world

7. Company Profiling

  • 1. Thermo Fisher Scientific
  • 2. Editas Medicine
  • 3. Caribou Biosciences
  • 4. CRISPR therapeutics
  • 5. Intellia
  • 6. Cellectis
  • 7. Horizon discovery PLC
  • 8. Sigma Aldrich
  • 9. Precision biosciences
  • 10. GenScript
  • 11. Sangamo Biosciences Inc.
  • 12. Lonza group limited
  • 13. Integrated DNA technologies
  • 14. New England Biolabs
  • 15. Oregene Technologies
  • 16. Transposgen Biopharmaceuticals
Back to Top